However, drugs developed that target Aβ or Tau alone are not satisfactory, suggesting that a deeper understanding of the pathogenesis of AD should be explored to reveal more comprehensive approaches to delay or prevent the development of AD. This evidence concerns the gene MAPT and Alzheimer disease.